Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Dsuvia: A Dull US FDA Review Preceded The Controversial Approval

Executive Summary

US FDA's review of AcelRx's opioid Dsuvia did not presage the external fireworks that came following the approval.

You may also be interested in...



Dsuvia Gets Warning Letter As US FDA’s Opioid Decisions Complicate Commissioner Race

AcelRx oversimplified Dsuvia’s ease of use, Office of Prescription Drug Promotion says. Focus on opioid safety comes as critics of Janet Woodcock have pointed to FDA’s decisions in the space as disqualifying her for FDA commissioner. Letter appears to reflect long-standing FDA concerns: Dsuvia was approved with a REMS related to administration issues, and Xeris received a similar warning letter last year for exaggerating the ease of use of its glucagon pre-filled syringe Gvoke PFS.

Campaign Against Woodcock’s US FDA Commissioner Bid Has Begun

Opioid issues delayed Robert Califf’s confirmation as FDA commissioner. Could they prevent the nomination of Janet Woodcock?

Variety Of Impacts COVID-19 Poses For Biopharma Reflected In Earnings Calls

Several firms reporting quarterly earnings this week discussed how the outbreak is affecting supply chains, drug launches and clinical trials.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS125564

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel